Mus­tang Bio to sell Mass­a­chu­setts CAR-T man­u­fac­tur­ing fa­cil­i­ty

The CAR-T-cen­tered biotech Mus­tang Bio is sell­ing off its man­u­fac­tur­ing fa­cil­i­ty in Mass­a­chu­setts for $11 mil­lion.

Mus­tang Bio an­nounced on Thurs­day that it will be sell­ing its 27,000-square-foot man­u­fac­tur­ing and an­a­lyt­i­cal test­ing fa­cil­i­ty in Worces­ter, MA, to cell and gene ther­a­py CD­MO uBri­Gene Bio­sciences. Per the terms of the deal, uBri­Gene will make a $6 mil­lion up­front pay­ment, with the oth­er $5 mil­lion payable up­on Mus­tang rais­ing $10 mil­lion from eq­ui­ty rais­es once the trans­ac­tion clos­es.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN